Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
You may also be interested in...
Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
Company is also on track to finalize commercial manufacturing for the once weekly form of Byetta in the second half of 2008.
Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
Company is also on track to finalize commercial manufacturing for the once weekly form of Byetta in the second half of 2008.
Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts
Driven by rising obesity rates, spending on diabetes therapies rose 14.5 percent from 2005 to 2006, firm’s annual Drug Trend Report states.